The compound represented by the following general formula is useful as a light emitting material. Ar.sup.1 represents an arylene group, Ar.sup.2 and Ar.sup.3 represent an aryl group, and R.sup.1 to R.sup.8 represent a hydrogen atom or a substituent, provided that at least one of R.sup.1 to R.sup.8 represents a diarylamino group. ##STR00001##

The compound represented by the following general formula is useful as a light emitting material. Ar.sup.1 represents an arylene group, Ar.sup.2 and Ar.sup.3 represent an aryl group, and R.sup.1 to R.sup.8 represent a hydrogen atom or a substituent, provided that at least one of R.sup.1 to R.sup.8 represents a diarylamino group. ##STR00001##

Provided is an organic light emitting element having stable performance in the air. The organic light emitting element includes: an anode; a cathode; and a first organic compound layer placed between the anode and the cathode, in which: the organic light emitting element further includes a first organic compound layer placed between the cathode and the emission layer, and a second organic compound layer placed between the emission layer and the first organic compound layer, and brought into contact with the first organic compound layer; the first organic compound layer contains a first organic compound; the second organic compound layer contains a second organic compound; and the first organic compound includes an organic compound represented by the following general formula [1], and the second organic compound includes an organic compound different from the first organic compound ##STR00001##

Provided is an organic light emitting element having stable performance in the air. The organic light emitting element includes: an anode; a cathode; and a first organic compound layer placed between the anode and the cathode, in which: the organic light emitting element further includes a first organic compound layer placed between the cathode and the emission layer, and a second organic compound layer placed between the emission layer and the first organic compound layer, and brought into contact with the first organic compound layer; the first organic compound layer contains a first organic compound; the second organic compound layer contains a second organic compound; and the first organic compound includes an organic compound represented by the following general formula [1], and the second organic compound includes an organic compound different from the first organic compound ##STR00001##

This disclosure relates to use of cashew nut shell liquid (CNSL) phenolics in the manufacture of molecules having ESIPT character, wherein said molecules are UVA and/or UVB absorbers, and further wherein said molecules are formulated as protectants against UVA and/or UVB radiation. The disclosure extends to use of CNSL in the manufacture of compositions including molecules having ESIPT character for treating and/or preventing sunburn and/or preventing U.V. damage.

This disclosure relates to use of cashew nut shell liquid (CNSL) phenolics in the manufacture of molecules having ESIPT character, wherein said molecules are UVA and/or UVB absorbers, and further wherein said molecules are formulated as protectants against UVA and/or UVB radiation. The disclosure extends to use of CNSL in the manufacture of compositions including molecules having ESIPT character for treating and/or preventing sunburn and/or preventing U.V. damage.

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

The present invention provides novel compounds having the general formula (I):

##STR00001##

wherein R.sup.1 to R.sup.3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.

An organic light emitting element produced by using a light emitting composition that contains both a first compound having a PBHT value more than 0.730 and a second compound having ES1 lower than that of the first compound and AEsT less than 0.20 eV is excellent in durability. ES1 is the lowest excited singlet energy level, AEsT is the difference between the lowest excited singlet energy level and the lowest excited triplet energy level.

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.